Sustainable tuberculosis drug development.

@article{Wallis2013SustainableTD,
  title={Sustainable tuberculosis drug development.},
  author={Robert S Wallis},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2013},
  volume={56 1},
  pages={106-13}
}
Six new antituberculosis compounds in 4 classes are presently in clinical trials. Although these show substantial promise for drug-resistant (DR) tuberculosis, the presently planned studies of these compounds will not inform their optimal use, as each will be tested singly vs placebo with existing drugs, rather than in new regimens. Each successive regulatory approval will increase the size, cost, and complexity of trials for those that follow, causing delays during which suboptimal use will… CONTINUE READING